[(18)F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
Authors
Glicksman, RMMetser, U
Valliant, J
Chung, PW
Fleshner, NE
Bristow, Robert G
Green, D
Finelli, A
Hamilton, R
Stanescu, T
Hussey, D
Catton, C
Gospodarowicz, M
Warde P
Bayley, A
Breen, S
Vines, D
Jaffray, DA
Berlin, A
Affiliation
Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.Issue Date
2020
Metadata
Show full item recordCitation
Glicksman RM, Metser U, Valliant J, Chung PW, Fleshner NE, Bristow RG, et al. [(18)F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open. 2020;10(4):e035959.Journal
BMJ OpenDOI
10.1136/bmjopen-2019-035959PubMed ID
32327479Additional Links
https://dx.doi.org/ 10.1136/bmjopen-2019-035959Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/bmjopen-2019-035959
Scopus Count
Collections
Related articles
- Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
- Authors: Glicksman RM, Metser U, Vines D, Valliant J, Liu Z, Chung PW, Bristow RG, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Green D, Bayley A, Helou J, Raman S, Kulkarni G, Catton C, Lam T, Chan R, Warde P, Gospodarowicz M, Jaffray DA, Berlin A
- Issue date: 2021 Sep
- Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
- Authors: Ong WL, Koh TL, Lim Joon D, Chao M, Farrugia B, Lau E, Khoo V, Lawrentschuk N, Bolton D, Foroudi F
- Issue date: 2019 Nov
- More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET/CT.
- Authors: Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE
- Issue date: 2019 Jan-Apr
- A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
- Authors: Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G
- Issue date: 2020 Mar 1
- Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for (18)F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease.
- Authors: Kim EH, Siegel BA, Teoh EJ, Andriole GL, LOCATE Study Group
- Issue date: 2021 Jun